Given the high lifetime risk of breast cancer (81–88%) in women carrying this mutation, a genetic analysis, including the detection of deleterious mutations to identify carriers of the BRCA2 mutation, is recommended [6,7]. This evidence concerns the gene BRCA2 and breast carcinoma.